Essentials
• The lack of factor (F) VIIa-endothelial protein C receptor (EPCR) binding in mice is unresolved.
• A single substitution of Leu4 to Phe in mouse FVIIa (mFVIIa) enables its interaction with EPCR.
• mFVIIa with a Phe4 shows EPCR binding-dependent enhanced hemostatic function in vivo vs. mFVIIa.
• Defining the FVIIa-EPCR interaction in mice allows for further investigating its biology in vivo.
Summary. Background: Human activated factor VII (hFVIIa), which is used in hemophilia treatment, binds to the endothelial protein C (PC) receptor (EPCR) with unclear hemostatic consequences. Interestingly, mice lack the activated FVII (FVIIa)-EPCR interaction. Therefore, to investigate the hemostatic consequences of this interaction in hemophilia, we previously engineered a mouse FVIIa (mFVIIa) molecule that bound mouse EPCR (mEPCR) by using three substitutions from mouse PC (mPC), i.e. Leu4?Phe, Leu8?Met, and Trp9?Arg. The resulting molecule, mFVIIa-FMR, modeled the EPCRbinding properties of hFVIIa and showed enhanced hemostatic capacity in hemophilic mice versus mFVIIa. These data implied a role of EPCR in the action of hFVIIa in hemophilia treatment. However, the substitutions in mFVIIa-FMR only broadly defined the sequence determinants for its mEPCR interaction and enhanced function in vivo. Objectives: To determine the individual contributions of mPC Phe4, Met8 and Arg9 to the in vitro/in vivo properties of mFVIIa-FMR. Methods: The mEPCR-binding properties of single amino acid variants of mFVIIa or mPC at position 4, 8 or 9 were investigated. Results and conclusions: Phe4 in mFVIIa or mPC was solely critical for interaction with mEPCR. In hemophilic mice, administration of mFVIIa harboring a Phe4 resulted in a 1.9-2.5-fold increased hemostatic capacity versus mFVIIa that was EPCR binding-dependent. This recapitulated previous observations made with
Introduction
The activated form of protein C (PC) cleaves activated factor V and VIII and regulates procoagulant reactions. The c-carboxyglutamic acid (Gla) domain-dependent binding of human PC to the endothelial PC receptor (EPCR) enhances activated PC (aPC) generation by~20-fold [1] , and is critically dependent on Leu8 in the PC/ aPC x-loop [2] . Remarkably, human FVII (hFVII) and its activated form (hFVIIa) also have Leu8 and bind to human EPCR with affinities similar to that of PC [2, 3] , but with unclear functional consequences. In mouse experiments using bolus hFVIIa infusions, EPCR has been shown to play a role in mediating tissue persistence and biodistribution of the administered hFVIIa [4, 5] . As high-dose hFVIIa is used as a hemostatic in hemophilia inhibitor patients, such observations imply a potential EPCR role in the hemostatic capacity of on-demand, or even prophylactic, hFVIIa administration in such patients.
Unfortunately, experimental validation of the hemostatic role of the hFVIIa-EPCR interaction is not feasible in mice, because: (i) hFVIIa interacts poorly with mouse tissue factor (TF) [6] ; and (ii) mice lack the endogenous FVII-EPCR interaction [7] [8] [9] . To address these shortcomings, we previously engineered a novel mouse FVIIa (mFVIIa) molecule that is capable of binding to mouse EPCR (mEPCR) as a gain-of-function [7] . The resulting molecule contained three amino acid substitutions from the corresponding mouse PC (mPC) Gla domain, all located within the x-loop (Leu4?Phe [L4F], Leu8?Met, and Trp9?Arg; molecule mFVIIa-FMR). This molecule bound mEPCR, but was otherwise functionally similar to mFVIIa in vitro, and it showed increased hemostatic function in injured hemophilic mice versus mFVIIa [7] . As mFVIIa-FMR simulated the TF/EPCR binding and functional properties of hFVIIa, our data suggested that the hFVIIa-EPCR interaction may contribute to the hemostatic action of hFVIIa administration in hemophilia.
Extensive data on the physiologic and pathologic effects of the PC-EPCR interaction have been obtained from mouse experiments. However, the specific Gla domain sequence determinants of the mPC-mEPCR interaction remain unclear. In our previous work, the Gla domain substitutions from mPC into mFVIIa-FMR enabled its binding to EPCR [7] , broadly suggesting that the mPC x-loop determines the PC-EPCR interaction in the mouse. Here, using the Gla domain of mFVIIa as a platform to probe the mPC-mEPCR interaction, we wanted to ascribe the role of the key residues Phe4, Met8 and Arg9 of the mPC Gla domain in that interaction. Moreover, we wanted to determine the contribution of these specific single residues in enhancing the hemostatic function of mFVIIa in vivo, as previously observed with mFVIIa-FMR [7] .
Materials and methods

Plasmid construction and protein purification
The mPC cDNA was obtained through gene synthesis (GenScript, Piscataway, NJ, USA) based on the mPC genomic DNA sequence (AF034569 [10] ). mFVIIa [11] , mPC and their variants were cloned in pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). Generation of HEK-293 stable cell lines, purification of recombinant mFVIIa, mFVIIa-L4F and mouse soluble EPCR (msEPCR) and protein quantification were performed as previously described [7] .
Binding assays
All binding assays were performed in the presence of 1.6 mM Ca 2+ and 0.6 mM Mg 2+ (pH 7.4). For transient transfections, 24-h conditioned medium diluted in binding buffer [7] was used. Determination of the binding constant for binding of recombinant mFVIIa-L4F to full-length mEPCR was performed following incubation (at 4°C) of increasing concentrations of the protease with CHO-K1 cells expressing mEPCR (or control CHO-K1 cells), as previously described [7] . Isothermal titration calorimetry (ITC) with mFVIIa-L4F and msEPCR and its data analysis were performed as previously described [7] .
Coagulation and thrombin generation assays
The activities of recombinant proteins were determined with a prothrombin time assay using hFVII-deficient plasma (George King Bio-Medical, Overland Park, KS, USA) and Innovin (Siemens Healthcare, Malvern, PA, USA), as previously described [7] . Thrombin generation by the use of mouse hemophilia B (HB) pooled plasma supplemented with increasing concentrations of mFVIIa or mFVIIa-L4F in dilution buffer (20 mM HEPES, 150 mM NaCl, 0.1% PEG-8000, pH 7.4) was performed as previously described [7] .
Animal experiments
All animal experiments were approved by the Institutional Animal Care and Use Committee at the Children's Hospital of Philadelphia. The infusion of mFVIIa or mFVIIa-L4F in mice for pharmacokinetic analysis, the FeCl 3 injury model and recombinant protein infusion in HB mice, with or without prior antibody administration, and the tail clip assay were performed as previously described [7] . Littermate, hemostatically normal mice were used as controls. When necessary, blood was collected from the retro-orbital plexus or tail vein in 3.8% sodium citrate.
Statistical analysis
Two-tailed Mann-Whitney U-tests were performed with GRAPHPAD PRISM v5.0b (GraphPad Software, Inc., La Jolla, CA, USA). Statistical differences were considered to be significant when the P-value was < 0.05.
Results and discussion
The Gla domain of human FVII/FVIIa/PC/aPC contains the determinants of the interaction with EPCR [2] , and the critical amino acid Leu8 is shared by these coagulation factors (Fig. 1A) . In mice, we have previously shown that amino acids at positions 4 (Phe), 8 (Met) and 9 (Arg) in the Gla domain of mature mPC, when placed into mFVIIa (in mFVIIa-FMR), are sufficient to enable mFVIIa binding to mEPCR embedded in the plasma membrane or in its soluble form [7] . A chimeric mFVIIa molecule (mFVIIa- ) harboring the entire mPC Gla domain showed affinity for mEPCR comparable to that of mFVIIa-FMR, suggesting that Phe4, Met8 and Arg9 in the mPC Gla domain confer both the affinity and specificity of its interaction with mEPCR [7] .
In order to probe the individual contributions of Phe4, Met8 and Arg9 to the mPC-mEPCR interaction and the unique in vivo properties of mFVIIa-FMR, we first generated mPC variants with single changes from the corresponding mFVIIa Gla domain at amino acid positions 4, 8, and 9, as mFVIIa interacts poorly with mEPCR. Conditioned medium from transiently transfected cells was used in binding assays on CHO-K1 cells stably expressing full-length mEPCR. We found that only the Phe4?Leu change in mPC abolished its binding to mEPCR (Fig. 1B) . In a reciprocal experiment, we generated mFVIIa variants with single changes from the corresponding mPC Gla domain at amino acid positions 4, 8, and 9. We found that the L4F change was sufficient to enable mEPCR binding to mFVIIa (Fig. 1C) . Together, our data suggest that Phe4 in the mPC Gla domain confers the specificity of the mPC-mEPCR interaction, and, when in mFVIIa, enables the interaction of the latter with mEPCR.
To further characterize the properties of mFVIIa with L4F, we purified recombinant mFVIIa-L4F ( Fig. 2A) and determined its affinity for full-length, cell-bound mEPCR. Using mEPCR-expressing CHO-K1 cells, we found that mFVIIa-L4F bound the receptor with an affinity of 370 AE 170 nM (Fig. 2B) . This was comparable to the receptor affinities that we had previously determined for mFVIIa-FMR (340 AE 70 nM) and mFVIIa-(1-43mPC) (190 AE 60 nM) [7] . We also utilized ITC in order to define the thermodymanics of interaction of mFVIIa-L4F with mEPCR. For this, we used msEPCR, as we have previously described in experiments with mFVIIa and its mPC-Gla domain chimeras [7] . In ITC, mFVIIa-L4F showed an affinity for msEPCR of 320 nM (Fig. 2C) , matching the affinity of the molecule for cell-surface expressed mEPCR (see above). Moreover, this was comparable to the affinity that we had determined for mFVIIa-(1-43mPC) (110 nM) under the same experimental conditions [7] . As mFVIIa-(1-43mPC) contains the full mPC Gla domain, its interaction with mEPCR is reflective of the mPC-mEPCR interaction. Therefore, our results collectively suggest, for the first time, that both the specificity and the affinity of the mPC-mEPCR interaction are critically dependent on Phe4 in the mPC Gla domain.
The property of mFVIIa-L4F binding to mEPCR allowed us to investigate whether a single Gla domain modification in mFVIIa is responsible for the enhanced hemostatic capacity of mFVIIa-FMR as compared with mFVIIa that we previously observed in hemophilic mice in vivo [7] . First, we determined the TF-dependent in vitro clotting activity of mFVIIa-L4F, and found it to be comparable to that of mFVIIa (Fig. 3A) . We also evaluated the capacity of mFVIIa-L4F to generate mouse thrombin in hemophilic plasma. In a thrombin generation assay, mFVIIa and mFVIIa-L4F showed similar profiles when added to mouse HB plasma (Fig. 3B [thrombin versus time] and inset [total thrombin]). These data collectively suggest that mFVIIa-L4F can bind mEPCR but is otherwise similar to mFVIIa in vitro, mimicking the properties of the triple mutant mFVIIa-FMR [7] .
In a pharmacokinetic analysis in mice, the plasma prothrombin clotting time at 5 min after mFVIIa-L4F infusion was significantly longer than that for mFVIIa ( Fig. 3C , P < 0.05). This was probably attributable to mFVIIa-L4F binding to mEPCR upon infusion, resulting in a reduced circulatory presence (and activity) as compared with mFVIIa, as previously observed for mFVIIa-FMR [7] . Subsequently, to assess hemostatic function in vivo, we performed an FeCl 3 injury on the carotid artery of HB mice, and followed this with protease infusion. We found that mFVIIa-L4F administration resulted in a lower vessel occlusion time (VOT) than mFVIIa (4.5 AE 2.4 min versus 8.9 AE 1.7 min, respectively; Fig. 3D , P < 0.05). Specifically, the VOT observed after mFVIIa-L4F administration was 50% AE 26% that after mFVIIa administration (control, 100%) (P < 0.05; Fig. 3E [gray bars] ), or 2.5 AE 1.2-fold faster. To investigate whether this effect was EPCR-dependent, we assessed mFVIIa-L4F administration in injured HB mice after antibody blocking of endogenous EPCR, or in isotype IgG-infused control HB mice. In particular, using an FeCl 3 carotid artery injury (as in Fig. 3D ), EPCR blocking resulted in a significant increase in the VOT as compared with the IgG control group (155% AE 31% versus 100% AE 13%, respectively, P < 0.05; Fig. 3E [black  bars] ). This indicates that the enhanced hemostatic capacity of mFVIIa-L4F in this injury model was endogenous EPCR binding-dependent. The hemostatic effects of mFVIIa-L4F were further assessed with another injury model in HB mice (tail clip, followed by protease infusion). As shown in Fig. 3F , administration of either mFVIIa or mFVIIa-L4F after tail clip resulted in reduced blood loss as compared with phosphate-buffered salinetreated HB mice ('after' period, P < 0.05). However, blood loss in the mFVIIa-L4F-treated mice was 1.9 AE 0.4-fold less than in the mFVIIa-treated mice (P < 0.05), consistent with mFVIIa-L4F's enhanced hemostatic capacity shown in Fig. 3D ,E.
Our in vivo results demonstrate that a single L4F mutation in the Gla domain of mFVIIa can enhance its hemostatic capacity in HB mice. Moreover, mFVIIa-L4F's pharmacokinetics and enhanced hemostatic properties and their EPCR dependency versus mFVIIa were comparable to previous observations made with mFVIIa-FMR [7] . Therefore, our data uniformly suggest that the L4F modification is solely responsible for the EPCRdependent enhanced hemostatic effects that we previously observed with the triple mutant mFVIIa-FMR [7] .
Previous work using mutagenesis has shown that, in humans, the PC-EPCR interaction is defined by Leu8 in the PC Gla domain [2] . Here, we describe Phe4 in mPC as being critical for the PC-EPCR interaction in the mouse, and show a sequence disparity between human and mouse with respect to the PC-EPCR interaction. Although human and mouse FVII share a Leu8, our data also provide the molecular explanation for this species difference in the FVII-EPCR interaction. Nevertheless, the physiologic relevance of the lack of the FVII-EPCR interaction in the mouse remains unclear. In humans, evidence for extravascular FVII persistence beyond its short half-life is provided by FVII-deficient patients, who can be maintained on hFVIIa prophylaxis two to three times a week [12] . This extended presence may be EPCR-dependent; in mice, tissue persistence of infused hFVIIa, which interacts with mEPCR, is positively correlated with endogenous EPCR levels [4] . It is possible that EPCR-dependent extravascular FVII transport may have a hemostatic function in humans that is unnecessary in the mouse. Further analysis of this interaction in other species may provide phylogenetic clues about its function; unfortunately, the lack of validated data on the FVII-EPCR interaction in different species remains a major limitation in this respect. ), and is shown as a percentage of that determined in the presence of IgG (control, 100%). Data are shown as mean AE 1 SD. *P < 0.05. In both panels, a dotted line indicates the 100% value. (F) HB or WT mice were subjected to a tail transection (diameter, 3 mm), and blood loss was measured for a period of 2 min ('Before' period). Immediately after this, 3 mg kg À1 mFVIIa or mFVIIa-L4F was infused, and blood loss was measured for an additional 8 min ('After' period). Quantitative assessment of blood loss was performed by measuring total hemoglobin by absorbance at 575 nm following red cell lysis, and converted to total blood loss (lL) by use of a standard curve. Individual animal data points are shown in addition to the mean AE 1 SD. *P < 0.05 versus WT mice; #P < 0.05 versus HB+mFVIIa mice. Blood loss between mouse cohorts was similar in the 'Before' period. NS, non-statistically significant difference; PT, prothrombin time.
mFVIIa-L4F showed enhanced hemostatic capacity versus mFVIIa in hemophilic mice. Although hFVIIa naturally binds endogenous EPCR, further modulation of this interaction may generate proteases with improved hemostatic capacity. The ability to enable or abolish EPCR binding to mFVIIa or mPC, respectively, as described here, may also enable the further characterization of the FVIIa-EPCR and PC-EPCR interactions in vivo, using appropriately generated novel mouse models.
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